United States Emerging Antibiotics Markets: Issues and Trends


Regular Price: USD 3,950.00

Special Price USD 2,765.00

30% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 2,765.00


Be the first to review this product

Table of Contents

United States Emerging Antibiotics Markets, Executive SummaryIssues and Trends in Emerging Antibiotic TherapiesIssues and Trends in Emerging Antibiotic TherapiesAntibiotics—A DefinitionAntibiotics—A DefinitionSummary of Major FindingsMarket Growth, Trends, and Total ForecastMajor Trends Affecting the Emerging Antibiotics Market Drivers Impacting the Emerging Antibiotics MarketRestraints Affecting the Emerging Antibiotics MarketConclusionsConclusionsUnited States Emerging Antibiotics Markets, Market Engineering Research MethodologyResearch ScopeObjectives and PurposeReport Structure and Market SegmentationMarket Engineering Forecasting MethodologyOverviewStrategic Significance of the Market Engineering ForecastJudging Credibility and Accuracy of Market Engineering ForecastsForecast AssumptionsUnited States Emerging Antibiotics Markets, Industry ChallengesIdentification of Challenges Facing the U.S. Emerging Antibiotics IndustryIdentification of Challenges Facing the U.S. Emerging Antibiotics IndustryMaintaining a Continuum of Products to Combat Evolving Resistance Ensures Continued Demand for Antibiotic TherapiesNeed for Responsible Marketing Campaigns to End-Users Creates Favorable Company ImageDesirable Drug Profile Ensures Patient ComplianceInfluencing Managed Care Decisions Secures Product in Hospital FormulariesStreamlining Identified Targets into Commercial Entities Poses Potential Difficulties and Bottlenecks Guidelines by Worldwide Health Organizations to Reduce Antibiotic Usage Create More Competitive EnvironmentHeavy Government Regulation Makes Drug Approval Process Uncertain for Antibiotic DrugsAntibiotics in Animal Feed Believed to Increase Resistance in Humans Prolonging Medical TherapiesMarket Engineering Research in the U.S. Antibiotics Market 1996-2006Market Overview and DefinitionsMarket Overview and DefinitionsOverview of the Antibiotics Market TodayHistorySegmentationFactors Influencing the Emerging Antibiotics MarketFactors Influencing the Emerging Antibiotics MarketMarket Drivers Market Drivers Continued Overprescription and Misprescription Increase Prevalence of ResistanceCost of Using More Expensive Novel Therapies Is Still Cheaper Than the Total Costs of Utilizing Traditional Therapies Genomics Technology Provides Many Potential Novel Target Candidates and Increases Probability of Drug DiscoveryPatent Expirations Lead to Generic Substitutions, Further Commoditizing Antibiotics Increasing Global Resistance Creates a Large Unmet Need for Effective AntibioticsPerceived Public Health Crisis Creates Willingness to Fund Novel Therapy Research Outside Traditional Pharmaceutical ArenaWidespread Internet Accessibility Provides Global Genomic and Epidemiological Information on Antibiotic Resistance, Leading to Better Information For Developing Novel ProductsWidespread Use of Antibiotics in Non-Therapeutic Environments Contributes to Increasing ResistanceAntibacterials Deemed Effective Against Specific Chronic Diseases Increase Prescriptions and Patient UseMarket RestraintsMarket RestraintsDownward Pricing Pressure of Existing Antibiotics Creates Larger Price Disparity for Novel TherapiesNew Government Policies Aim to Monitor and Reduce Antibiotic UsageImproved Novel Vaccine Therapies Will Likely Prevent Many Serious Infections from OccurringComplexity of Antibiotic Development and Approval Processes Thwarts Product DevelopmentDespite Need, Attractive International Markets Are Limited to the Western WorldFuture Studies Are Expected to Link Antibiotic Usage to Negative Health EffectsHealth Programs to Curb Bacterial Resistance Will Prolong Effectiveness of Older TherapiesPresence of Alternative Products Increases the Competitive EnvironmentAs European Biotech Companies Gain Momentum, Increased Competition for Novel Therapies and Pharmaceutical Collaborations Will ResultIncreased Occurrence and Awareness of Antibiotic Resistance Will Likely Prevent Over-the-Counter IntroductionsUnited States Emerging Antibiotics Markets, Issues and Trends in the U.S. Emerging Antibiotics Market 1996-2006IntroductionIntroductionTrends in Rates of Bacterial ResistanceTrends in Rates of Bacterial ResistanceTrends in Clinically Important Resistant PathogensPenicillin-Resistant Streptococcus Pneumonae (PRSP)Methicillin-Resistant Staphylococcus Aureus (MRSA)Vancomycin Intermediate Staphylococcus Aureus (VISA) and Vancomycin Resistant Staphylococcus Aureus (VRSA or RSA)Vancomycin-Resistant Enterococci (VRE or VREF)Multidrug-Resistant Tuberculosis (MDR-TB)Trends and Factors Affecting Increased ResistanceInjudicious and Inappropriate Use in Human Therapeutics Overuse and Unnecessary Use of Antibiotics in Animals and AgricultureA Global ProblemThe Costs of Antibiotic Resistance Continue to RiseMethod of DeliveryThe Connection Between Antiseptic and Antibiotic ProductsTrends in Diseases Due to Bacterial InfectionsTrends in Diseases Due to Bacterial InfectionsRespiratory Tract InfectionsPeptic UlcersOtitis Media Foot Infections Due to DiabetesBacteremiaTrends in Physician PerspectivesTrends in Physician PerspectivesTrends in Patient PerspectivesTrends in Patient PerspectivesTrends in At-Risk Patient PopulationsImmunocompromised PatientsPatients in ICU WardsThe ElderlyRespiratory Disease or Cardiovascular Disorder PatientsChildren The Impact of DiagnosticsThe Impact of DiagnosticsImpact of Developing Antibacterial VaccinesImpact of Developing Antibacterial VaccinesAn Industry Built on Strategic AlliancesAn Industry Built on Strategic AlliancesTrends in Bacterial GenomicsTrends in Bacterial GenomicsTrends in HealthcareManaged CareMedicareThe Public Health BurdenThe Impact of the Center of Disease Control and Prevention (CDC)The Impact of the Center of Disease Control and Prevention (CDC)United States Emerging Antibiotics Markets, Research and Development in the U.S. Emerging Antibiotics Market 1996-2006IntroductionIntroductionNewly Approved AntibioticsNewly Approved AntibioticsQuinupristin/dalfopristinThe QuinolonesLevaquinMoxifloxacinGatifloxacinDrugs Filed for ApprovalGemifloxacinLinezolidEvernomicinCefditoren pivoxilCurrent Research and Future DiscoveriesCurrent Research and Future DiscoveriesGlycylcyclinesVancomycin Comparable Agents and DescendantsKetolidesBeta-LactamsOligosaccharide CompoundsPeptide ProductsPeptide ProductsPexigananNeuprexProtegrinsBactolysins and EnhansinsSynthetic PeptidesOligonucleotide AgentsOligonucleotide AgentsPhage ProductsPhage ProductsInhibiting AdhesionImpact of GenomicsSpecialty Pharmaceutical Companies: Biotech Companies Founded Solely to Develop Anti-Infective Drugs Pharmaceutical CompaniesAlternatives TherapiesLasersIonic Silver ComplexBioanalysis ChipsBioanalysis ChipsSurveillance ProgramsSurveillance ProgramsUnited States Emerging Antibiotics Markets, Strategies for the U.S. Emerging Antibiotic Therapies Market 1996-2006What Is Market Engineering Strategy?What Is Market Engineering Strategy?Measurement-Driven Strategy GenerationMarket Engineering Strategic RecommendationsMarket Engineering Strategic RecommendationsCorporate Management Research and DevelopmentMarketing DepartmentMarket Engineering Awards for the U.S. Emerging Antibiotics MarketFrost & Sullivan's 2000 Market Engineering AwardsFrost & Sullivan's 2000 Market Engineering AwardsMarket Engineering AwardsThe 2000 Market Engineering Product Innovation AwardThe 2000 Market Engineering Antibacterial Program AwardThe 2000 Market Engineering Entrepreneurial Company AwardThe 2000 Market Engineering Customer Focus Award

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.